Subsequently, ABT-199 (venetoclax) was developed, a highly selective BCL-2 inhibitor that has been approved for patients with chronic lymphocytic leukemia (CLL) harbouring 17p deletion who have received at least one prior treatment [68]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.